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Table 1

Abstract

Kaposi's sarcoma-associated herpesvirus is an enveloped virus that contains
glycoproteins which enable viral spread from host to host, attachment to the host cell, and
host specificity. Herpesviruses are made up of different subfamilies including: alpha,
beta and gamma and specific glycoproteins are conserved among the subfamilies. It has
been observed that the murine gamma-herpesvirus 68 (MHV-68) contains an open
reading frame (ORF) 27 which encodes a type I1 transmembrane glycoprotein. MHV-68
ORF27 is expressed on the outside of infected cells but is found intracellularly when
expressed alone in cells. Another O W found in MHV-68,ORF58, was discovered to be
essential in the proper translocation of MHV-68 ORF27 from the cytoplasm of the cell to
the surface of the infected cell. OW58 deficient cells revealed that OW27 was produced
in typical amounts but was located to the endoplasmic reticulum. When both genes were
co-expressed they formed a protein complex which reached the cell surface. There is
nucleotide sequence homology between MHV-68 OW27 and KSHV ORF27 (42%
similarity), and between MHV-68 ORF58 and KSHV OW58 (41% similarity)
suggesting the proteins would have similar functions. In this study, I will attempt to
investigate the localization and co-localization of KSHV ORF27 and KSHV ORF58
when expressed alone and together. KSHV ORF27 and ORF58 plasmid constructs were
transfected into Vero cells and localization of OW27 was observed within the cytoplasm
of the cell using immunofluorescence. KSHV ORF58 protein was not expressed
properly; therefore, localization within the cell was not observed. Further experiments
must be carried out to determine what is happening to the KSHV ORF58 protein.

Introduction
Dr. Moritz Kaposi first documented purple lesions affecting elderly men,
particularly of Mediterranean decent, in 1872, and since then the disease associated with
these lesions, known as endothelial neoplasms, is referred to as Kaposi's sarcoma (KS)
(Dourmishev et al., 2003). A new human herpesvirus was discovered within the lesions
of KS patients and was termed Kaposi's sarcoma-associated herpesvirus (KSHV), also
known as human herpesvirus 8 (Changet al., 1994). KSHV DNA has been isolated from
people suffering from KS, multicentric Castleman's disease (MCD) and primary effusion
lymphoma (PEL) (Ablashi et al., 2002).
KS is a vascular tumor made up of many different cell types including endothelial
cells, erythrocytes, inflammatory cells and elongated endothelial cells known as "spindle"
cells (Dourmishev et al., 2003; Lint et al., 2009). Red blood cells are often present in the
lesions and are found between the spindle cells, giving the "purple" color to the lesion.
As the disease progresses, the spindle cells ultimately are the major cell population at
which point they begin to compress the vascular slits causing the lesions to become
nodular (Ablashi et al., 2002). KSHV was found 95% of the time in vascular endothelial
cells and "spindle" cells of KS lesions (Ablashi et al., 2002; Russo et al., 1996; Wen et
al., 2010).

KSHV has been associated with all four forms of KS, which are classified as:
classic (Mediterranean region), epidemic (AIDS-associated), endemic (African region)
and iatrogenic (transplant recipients) (Ablashi et al., 2002; Dourmishev et al., 2003).
Classic KS, described by Dr. Kaposi, usually occurs in MediterraneadEastem European

elderly men (Hengge et al., 2002b). KS occurrence in the Mediterranean is about tenfold higher than Europe and the United States (Dourmishev et al., 2003). The lesions and
nodules are normally located on the extremities of the body with little involvement of
internal organs or lymph nodes (Hengge et al., 2002b).
AIDS-associated KS can spread both viscerally and through the lymph system
more so than any other form (Wen et al., 2010). Approximately 30% of AIDS patients
exhibited KS as the first symptom of AIDS (Greene et al., 2007); as a result, KS was
considered an AIDS defining illness (Wen et al., 2010). AIDS-KS affects the skin,
lymph nodes, and may also include lungs, gastrointestinal tract, liver and spleen (Ablashi
et al., 2002). AIDS-KS is usually found on the head and neck and develops rapidly
(Dourmishev et al., 2003). KS lesions can become tumors and visceral diffusions, which
can lead to organ failure and finally death (Dourmishev et al., 2003). KS is still the most
prevalent AIDS-associated cancer in the world (Wen et al., 2010).
Endemic KS is traditionally found throughout Eastern and Central Africa, and it
affects younger and older people (Wen et al., 2010). It is found in four distinct disease
patterns: similar to classic KS; a more aggressive form invading soft tissue and bone;
florid mucocutaneous and visceral disease; and fulminant lymphadenopathic disease
which quickly progresses to lymph nodes and visceral organs (Hengge et al., 2002b).
The more aggressive form of endemic KS commonly afflicts children and has a very high
mortality rate (Wen et al., 2010).
The final form of KS is post-transplanthatrogenic KS. Post-transplant KS occurs
after the immune system has been suppressed for a long period of time by the therapy

used to avoid rejection of a transplanted organ (Wen et al., 2010). Iatrogenic KS may
become chronic or even progress quickly, but spontaneous remission will most likely
occur after removal of immunosuppressive drugs (Hengge et al., 2002b).
KSHV has also been strongly associated with two B cell diseases, PEL and
multicentric Castleman's disease (MCD) (Lint et al., 2009). KSHV viral DNA was found
in lymphomas, a cancer of the lymphatic system, within the body cavities of AIDS
patients and were referred to as body cavity-based lymphomas (BCBL), also known as
primary effusion lymphoma (PEL) (Ablashi et al., 2002; Wen et al., 2010). PEL operates
as a classic tumor in that every cell carries KSHV DNA (Chen et al., 2007; Lint et al.,
2009). The lymphomas contain high copy numbers of viral DNA-anywhere

from 50 to

150 KSHV episomes per infected cell (Wen et al., 2010). The high copy number allows
the virus to be identified easily by Southern blot analysis; this is unlike KS tissues which
have few copies per cell and only PCR can be used for detection (Ablashi et al., 2002).
PEL is very rare and is observed in the last stages of AIDS (Lint et al., 2009). It is
identified by over growth of malignant B cells in the body cavity primarily in the pleura,
pericardium and peritoneum (Chen et al., 2007; Lint et al., 2009; Wen et al., 2010). PEL
is aggressive and progresses rapidly leading to h g h mortality rates. Survival after
diagnosis can typically be anywhere from two to five months (Ablashi et al., 2002; Chen
et al., 2007; Wen et al., 2010).
Castleman's disease is a rare lymphoproliferative disease typically depicted as a
polyclonal, non-neoplastic disorder (Wen et al., 2010). The most common form is the
hyaline vascular type described as a solitary localized mass usually in a lymph node, that

can be surgwally removed (Ablashi et al., 2002; Lint et al., 2009). The second and more
aggressive form, known as the plasma cell type, is associated with widespread
lymphadenopathy (Hengge et al., 2002a; Wen et al., 2010). MCD is most commonly
seen in AIDS patients and is characterized by germinal center expansion and vascular
endothelial proliferation in the lymph nodes (Wen et al., 2010). KSHV is present in
virtually all cases of AIDS-related MCD (Ablashi et al., 2002; Lint et al., 2009). It is
common for MCD patients to develop KS and non-Hodgkin's lymphoma as well, but
KSHV is almost always present even if KS does not develop (Ablashi et al., 2002).
Many people are infected with KSHV but its seroprevalence in the population
differs among the affected groups. In African countries, KSHV is observed in about 40
to 60% of the general population reaching a high prevalence rate (Lint et al., 2009). The
endemic areas have primary infection of KSHV occurring in childhood, and the number
of infected individuals increases with age (Pelser et al., 2009). Transmission of the virus
in endemic regions is primarily driven within the family, from parent to child and
between family members. The most likely transmission method is salivary exchange
(Ablashi et al., 2002; Lint et al., 2009). The Mediterranean populations are found to have
anywhere from 10 to 25% seroprevalence of the virus, which is why classic KS is most
often diagnosed in the regions surrounding the Mediterranean (Ablashi et al., 2002). The
prevalence of KSHV in the rest of the world ranges from two to five percent, and is
spread like a sexually transmitted disease despite the low viral load in semen of infected
individuals (Ablashi et al., 2002; Lint et al., 2009).

Herpesviridae
The herpesvirus virion is made up of four major components: a nucleoprotein core
which encapsulates a double-stranded linear DNA genome; an icosahedral capsid which
surrounds the core; an unstructured dense protein layer, referred to as the tegument; and a
lipid envelope containing different viral glycoproteins (Lint et al., 2009; Zhu et al.,
2005). Production of viral DNA and assembly of the capsid occur in the nucleus of the
infected cell. During herpesvirus infection, virus-specific areas are created in the
nucleus, designated as replication compartments. These compartments are where viral
DNA replication, late gene expression and encapsidation of progeny genomes occur.
These compartments cause the formation of basophilic nuclear inclusion bodies, which is
a diagnostic feature of herpesvirus infection. Production of virion particles is usually
accompanied by death of the infected cell (Lint et al., 2009).
The herpesviridae family is made up of three subfamilies designated as a, P and y.
The a-herpesviruses are grouped together based on their variable host range, short
reproductive cycle, efficient destruction of infected cells, and ability to establish latent
infections primarily in sensory ganglia (Knipe et al., 2001). The human herpes viruses
(HHV) in the alpha subfamily include: HHVI, HHV2 and HHV3 (Knipe et al., 2001).
The P-herpesviruses are characterized by their long reproductive cycle, slow progression
of infection in culture, and possible enlargement of infected cells (Knipe et al., 2001).
The human herpes viruses in the beta subfamily include: HHVS, HHV6 and HHV7
(Knipe et al., 2001). The y-herpesviruses are grouped together based on their capability
to replicate in epithelial cells, establish either latency or lytic infections in lymphocytes,

and cause cancer (Knipe et al., 2001; Lint et al., 2009). There are two genera in the yherpesvirus subfamily: the lyrnphocryptovirus genus, which includes Epstein-Barr virus
(EBV), and the rhadinovirus genus, which includes: HHV4, KSHV and murine herpes
virus 68 (MHV-68) (Knipe et al., 2001; Lint et al., 2009). The y-herpesviruses are
known to establish viral infection and evade detection by actively suppressing apoptosis
and escaping immune detection (Wen et al., 2010). They can alter cell cycle progression,
apoptosis and immune surveillance allowing the virus to increase its odds of survival
(Wen et al., 2010).
KSHV Life Cycle
The KSHV genome is approximately 165 kb long, contains more than 81 open
reading frames (ORF), and can encode up to 90 viral proteins (Russo et al., 1996). The
linear double stranded DNA viral genome has a central region with a low GC make up
known as the long unique region (LUR); this region is flanked on both ends by terminal
repeats (TR) which are highly GC rich (Hengge et al., 2002a; Russo et al., 1996; Wen et
al., 2010). Even though numerous ORFs of KSHV are conserved, there are KSHV
specific ORFs not seen in other herpesviruses. The KSHV specific ORFs are identified
as K1 to K15 (Russo et al., 1996; Wen et al., 2010). Attachment to a host cell is made
possible by glycoproteins (gB, ORF4, gWgL, gM/gN and gpK8.1A) binding with
receptors like heparan sulfate (HS), DC-SIGN (dendritic cell-specific intercellular
adhesion molecule 3 (ICAM-3)-grabbing non-integrin), integrins and other unknown
ligands found on the surface of the cell (Akula et al., 2001; Rappociolo et al., 2006).
Binding to receptors leads to the start of signaling pathways that will either cause fusion

of the virion envelope to the cell membrane or endocytosis of the virion (Chandran et al.,
2010; Greene et al., 2009).
The pathway of entry is dependent on the cell type, for example, clathrinmediated endocytosis has been observed in endothelial, epithelial and fibroblast cells
(Akula et al., 2003; Chandran et al., 2010; Greene et al., 2009). Attachment and entry is
then followed by transportation of the endocytotic vesicle, containing the virion, to the
nucleus (Raghu et al., 2009). Similar to other herpesviruses, DNA replication occurs via
the rolling circle mechanism in the replication compartments in the nucleus (Knipe et al.,
2001). Like other herpesviruses, KSHV exhibits both latent and lytic phases in infected
cells (Sharma-Walia et al., 2006).
After entry into the cell, polymerized microtubules deliver the viral DNA to the
nucleus (Naranatt et al., 2005). At this point a latent infection is established and the viral
genome is replicated as an episome (Greene et al., 2007; Hengge et al., 2002a; Lint et al.,
2009). There are very few viral genes that are expressed during latency. Some of the
latent viral genes include the latent nuclear antigen (LANA/ORF73), viral cyclin (vcyclin/ORF72), viral Fas-associated death domain (FADD) interleukin-lL-converting
enzyme (FLICE) inhibitory protein (v-FLIPlK13) and kaposin (K12); all are located
adjacent to one another in the genome (Chandran et al., 2010; Jenner et al., 2002;
Pyakurel et al., 2007).
During latent infection the latently expressed genes prevent apoptosis of the cell,
ensure the viral genome is dispersed to progeny cells, and drive the cell cycle forward
(Jenner et al., 2002; Lint et al., 2009; Pyakurel et al., 2007). For example, LANA

competes with E2F (a transcription factor) for binding of retinoblastoma protein (Rb)
(Pyakurel et al., 2007) which leads to further progression of the cell cycle. V-cyclin
promotes progression of the cell cycle when it binds with cyclin dependent kinase 6
which, will in turn, phosphorylate Rb (Verschuren et al., 2004). Phosphorylated Rb will
release bound E2F (Verschuren et al., 2004). Free E2F activates the transcription of S
phase genes moving the cell cycle forward (Pyakurel et al., 2007; Verschuren et al.,
2004).
In latent cells, no infectious virus particles are being produced, but when induced
into reactivation, KSHV enters the lytic phase (Wen et al., 2010; Zhu et al., 2005).
Triggering a cell to go from latency to lytic infection is mediated by the replication and
transcription activator (Rta) protein, which is a viral transcriptional activator able to
induce lytic gene expression alone (Chen et al., 2009; Greene et al., 2007; Lint et al.,
2009; Nakamura et al., 2003). During latency Rta expression is repressed (Greene et al.,
2007). It has been shown that deletion of Rta inhibits both spontaneous and chemical
induction of the lytic cycle (Lint et al., 2009). When the cell is triggered to enter the lytic
cycle, expression of the viral genes is initiated in a sequential manner beginning with the
immediate early (IE), early (E) and late (L) genes (Lint et al., 2009).
The IE genes regulate the subsequent transcriptional cascade; Rta, the "switch"
protein, is required to initiate the lytic replication cycle (Greene et al., 2007; Wen et al.,
2010). The first genes to be expressed after induction encode regulators of gene
expression such as ORF50, K8 and OW45 (Jenner et al., 2002). The IE gene K8 appears
to balance Rta's transactivation activity (Rossetto et al., 2007) and OW45 aids in the

suppression of interferon induction (Zhu et al., 2002). These IE genes are followed by E
genes which assist in viral DNA replication (Lu et al., 2004). L genes take part in the
construction and maturation of virions (Jenner et al., 2002; Lu et al., 2004).
Glycoproteins are late genes; they are membrane proteins found on the lipid envelope of
virions (Knipe et al., 2001).
Glycoproteins

Glycoproteins play a major role in cell to cell interactions including attachment
and entry into host cells (Knipe et al., 2001). Fusion of the virion envelope with host cell
membranes is primarily mediated by viral glycoproteins; viral glycoproteins can also aid
in virion egression (Subramanian et al., 2010). Glycoproteins are created on membrane
bound ribosomes, translocated to the endoplasmic reticulum (ER) and are typically
transferred to the plasma membrane via the trans-Golgi network (TGN) (Veit et al.,
1996). KSHV encodes many glycoproteins which are conserved in the herpesviridae
including: gB, gH, gL, gM and gN (Chandran et al., 2010; Zhu et al., 2005). KSHV also
encodes unique glycoproteins which include: K1, ORF4, K8.1A, K8.1B, K14 and K15
(Chandran et al., 2010; Zhu et al., 2005). K8.1 gene encodes two glycoproteins produced
from spliced transcripts, K8.1A and K8.1B. K8.1A is the most abundant of the two
(Chandran et al., 2010; Chandran et al., 1998; Zhu et al., 2005). Birkmann et al. (2001)
examined the binding of K8.l to mammalian cells using soluble K8.1 protein. It was
found that both K8.1 protein derivatives are capable of binding to cell surface heparin
sulfate (HS) (Ablashi et al., 2002; Birkmann et al., 2001; Zhu et al., 2005). Furthermore,
soluble HS blocked infection of endothelial cells by KSHV (Birkmann et al., 2001).

Viral glycoproteins are very important in the spread and attachment of the virus particle;
therefore, it is imperative that we examine all known and any possible KSHV
glycoproteins.

O W 2 7 and ORF58
There are two other possible glycoproteins or membrane associated proteins in
KSHV, ORF27 and OW58 (Chandran et al., 1998; Russo et al., 1996), but their
functions have not yet been determined. KSHV OW27 is homologous to EBV BDLF2
(43.3 % similarity) and MHV-68 ORF27 (42% similarity) (May et al., 2005a; Russo et
al., 1996). BDLF2 was thought to be a virion tegument protein poorly conserved among

y-herpesviruses (Johannsen et al., 2004; Tarbouriech et al., 2006), but was actually found
to be the eleventh glycoprotein of EBV (Gore et al., 2009). BDLF2 encodes a
transmembrane domain protein with N-linked glycosylation sites which classifies BDLF2
as a type I1 envelope glycoprotein (Gore et al., 2009). MHV-68 ORF27 was also found
to be a glycoprotein, analogous to BDLF2, that plays a role in cell to cell viral spread, but
also restricts host antibody access to the sensitive extracellular loop of the MHV-68
OW58 glycoprotein (May et al., 2005a). Zhu et al. (2005) purified KSHV virions and
determined all proteins present within the virion. The KSHV OW27 protein was found
in the purified virions but localization within the virion was not determined (Zhu et al.,
2005). Rozen et al. (2008) observed virion protein interactions and found KSHV ORF27
interacted with two envelope glycoproteins (ORF47 and ORF53) and ORF45, a tegument
protein. After examination of KSHV ORF27 homologues and its association with
purified virions, I hypothesize that KSHV OW27 is a possible glywprotein.

KSHV ORF58 is homologous to EBV BMRF2 (50.6 % similarity) (Russo et al.,
1996) and MHV-68 OW58 (41 % similarity) (May et al., 2005a). BMRF2, a highly
hydrophobic multi-spanning transmembrane protein, has been observed to be crucial to
EBV infection of epithelial cells (Tarbouriech et al., 2006; Xiao et al., 2007). An

arginine-glycine-aspartic acid (RGD) motif was discovered in the main extracellular
loop of BMRF2 (Xiao et al., 2009). RGD motifs interact with many extracellular matrix
proteins that interact with host cell surface integrins (Akula et al., 2002). The
interactions with integrins can activate many integrin associated pathways which could
lead to virion attachment and entry or cell to cell spread (Xiao et al., 2007). BMRF2 was
not crucial to the egress of infectious EBV particles, supporting the idea that the protein
may actually help in cell to cell spread (Loesing et al., 2009; Xiao et al., 2008). EBV
BMRF2 protein has been observed in mature virions (Xiao et al., 2007). MHV-68
OW58 also encodes a type I1 multi-membrane spanning protein which can bind to cells
via an extracellular loop (EC4), similar to the RGD containing loop found in BMRF2
(May et al., 2005a; Xiao et al., 2009). KSHV ORF58 encodes a highly hydrophobic
protein which has many potential transmembrane regions (Chan et al., 1998). KSHV
ORF58 was predicted to be a type IIIa or 11% plasma membrane associated protein (Chan
et al., 1998). The similarities between the ORF58 homologues lead us to speculate that

KSHV ORF58 protein may also be a glycoprotein.
Identifying the expression patterns of OW27 and 58 may help in understanding
their role in the virus life cycle. Gene expression patterns can be determined using many
different techniques. The various methods will help to determine the true expression

pattern of a gene. Nakamura et al. (2003) developed a multiprobe RNase protection
assay to examine all KSHV genes expression patterns after induction. Yoo et al. (2005)
established an infection in endothelial cells using a recombinant KSHV expression
vector; and whole genome RT-qPCR was then used to evaluate expression patterns of
KSHV transcripts after infection. Anti-viral drugs can also be used to study expression
patterns. Lu et al. (2004) used cidofovir (CDV), an inhibitor of viral DNA replication, to
examine KSHV gene expression. CDV will cause inhibition of viral DNA synthesis and
replication by being incorporated into the replicating DNA which terminates the strand
(De Clercq et al., 2003). CDV allows for the detection of late viral transcripts, which
would rely on viral DNA replication, from other transcripts (De Clercq et al., 2003).
Nakamura et al. (2003) found KSHV OW27 to be late, meaning expression rate
surpassed two-fold amplification after 16 hours and continued to increase. OW27 would
be expected to be expressed late in the replication cycle if it were a glycoprotein. Yoo et

al. (2005) also observed a late expression pattern for KSHV ORF27. Lu et al. (2004)
found OW27 was sensitive to CDV. Many of the genes sensitive to CDV were virion
structural proteins (Lu et al., 2004). Ebrahimi et al. (2003) identified late transcripts with
phosphonoacetic acid treatment (another viral DNA polymerase inhibitor) prior to
infection with MHV-68. Total RNA was isolated and analyzed by DNA microarrays.
MHV-68 OW27 was identified as a late expressing transcript (Ebrahimi et al., 2003).
Similar to its homologues, EBV BDLF2 was also observed having a late expression
pattern (Tarbouriech et al., 2006).

Nakamura et al. (2003) found KSHV ORF58 had an immediate-early expression
pattern, corresponding to a greater than or equal to two-fold increase prior to 12 hours
with expression reaching its apex at 24 hours. Interestingly, ORF58 mRNA expression
was not observed late in the cycle as would have been expected. Contrary to Nakamura
et al. (2003) findings for KSHV ORF58, Yoo et al. (2005) determined, with the use of

the KSHV recombinant expression vector, KSHV ORF58 had a late expression pattern.

Lu et al. (2004) found KSHV ORF58 was insensitive to CDV which would mean ORF58
was not a late expressing transcript. On the other hand, Lu et al. (2004) observed only
-25% of genes with glycoprotein homology were CDV sensitive. The remaining
glycoproteins were CDV insensitive with expression occurring early in the lytic cycle (Lu
et al., 2004). This early expression may allow time for post-translational modification or

targeting of the protein to other locations within the cell (Lu et al., 2004). EBV BMRF2
mRNA expression occurred during the lytic cycle (Loesing et al., 2009; Xiao et al.,
2007). Ebrahimi et al. (2003) identified MHV-68 OW58 as a late expressing transcript.
Sander et al. (2007) identified the localization patterns of KSHV ORF27 and
ORF58 using expression plasmids. KSHV OW58 was subcellularly localized in the
TGN (Sander et al., 2007). KSHV OW27 was observed to throughout the cytoplasm
heterogeneously (Sander et al., 2007). Localization of the EBV homologues depended
on the presence of other proteins (Gore et al., 2009). When expressed alone BDLF2 did
not travel from the ER to the TGN (Gore et al., 2009; Loesing et al., 2009). Yet, when it
was co-expressed with BMRF2, BDLF2 co-localized and translocated to the cell
membrane (Gore et al., 2009). Therefore, BDLF2 translocation and correct processing is

dependent on BMRF2 (Gore et al., 2009; Loesing et al., 2009). Studies show that
BDLF2 and BMRF2 form a stable complex (Gore et al., 2009; Xiao et al., 2009).
Correct processing of MHV-68 OW27 and its transportation from the ER to the cell
plasma membrane also only occured when co-expressed with MHV-68 ORF58 (May et
al., 2005a), similar to the EBV BDLF2 protein. In cells expressing only MHV-68
ORF27, the protein was localized strictly within the cell at the ER (May et al., 2005a).
MHV-68 OW27 and ORF58 also form a protein complex that aids in cell to cell spread
of the virus (May et al., 2005a).
KSHV ORF27 and ORF58 sequence homology to EBV and MHV-68 suggests
their functions may also be similar. In order to investigate this hypothesis, KSHV
OW27 and ORF58 were cloned. OW27 fusion protein was expressed in mammalian
cells. After expression was verified via western blot analysis, ORF27 fusion protein was
visualized using confocal microscopy to illustrate localization of OW27 in the cytoplasm
of the cell.

Materials and Methods
Sequence Alignment
KSHV ORF27, EBV BDLF2 and MHV68 OW27 were aligned using ClustalW2,
(http://\nnv.ebi.ac.ukiclustalw2/), using the following accession numbers: KSHV OW27

- AAC57108.1, EBV BDLF2 - CAD53445.1, MHV68 OW27 - AAB66398.1. KSHV
ORF58, EBV-BMRF2 and MHV68 OW58 were also aligned using the ClustalW2
program. The following accession numbers were used in the OW58 alignment: KSHV
OW58 - AAC57143.1, EBV-BMRF2 - CAD53408.1, MHV68 OW58 - AAB66448.1.
The protein sequences of the OW27 homologues were also analyzed for possible Nlinked glycosylation sites using NetNGlyc 1.0 Server, a prediction program (Blom et al.,
2004). http:/luw.cbs.dtu.dWservices~etNGlyc/

Cloning of ORF 58 and 27
KSHV OW58 was cloned into p3XFLAG-CMV-14 (Sigma-Aldrich) and
p3XFLAG-CMV-26 (Sigma-Aldrich). KSHV OW27 was cloned into phCMV2
(Genlantis). Gene inserts were amplified using PCR. Body-cavity-based lymphoma cell
line (BCBL-1) genomic DNA was used as the template. The thennocycler conditions for
denaturation, annealing and extension are listed on Table 1,30 cycles were used to
amplify the genes. The polymerase chain reaction (PCR) consisted of the following: 50
n g l ~ BCBL-1
1
template DNA, 50 pmol of primer mix, 10 mM dNTP mix, 1X PCR
Buffer (USB) and 1 p1 FideliTaq DNA Polymerase (USB) in a 50 p1 reaction with RNase
free water, some reactions had an additional 1 mM MgC12. PCR products were then

electrophoresed on a 1.0% (wlv) agarose gel in 1X Tris-acetate-EDTA buffer (TAE; 400
mM Tris-acetate, 10 mM EDTA)-containing 0.5 pgl ml ethidium bromide. The PCR

products were then gel purified using the QIAquick Gel Extraction Kit (Qiagen)
according to manufacturer's instructions.
All purified PCR products and vector plasmids were digested with Bgl I1
(Promega) and Eco RI (Promega) restriction enzymes. After digestion, PCR products
and vectors were purified using the Charge Switch Kit (Invitrogen) before ligation. The
ligation reaction consisted of T4 DNA ligase (Promega), 1X ligase buffer (Promega),
purified PCR and plasmid products (double digested) in a total volume of 20 p1. Control
ligations, which did not include the gene of interest, were also prepared. The ligation
reactions were then incubated overnight at 16OC. The OW58127 constructs were then
transformed into Escherichia coli (E. coli) DH5a cells (described in detail below).
Colonies from the transformation were grown in Luria broth (LB) with ampicillin or
kanamycin (100 pgl pl), depending on the plasmid used, overnight at 37OC. The
plasmid-insert construct DNA was then isolated from the overnight cell culture using
Quantum Prep Plasmid mini-prep kit (Bio Rad). The isolated DNA was double digested
with the appropriate restriction enzymes and the reaction was electrophoresed in a 1%
agarose gel to check for the presence of the KSHV gene inserts. To verify the inserts
were correctly cloned the presumptive positive clones were sent to Genewiz
(htt~://www.renewiz.com/)for sequencing.

Insert

3' primer

5' primer

aaagatctwxaacaactttatttattaccg

aagaattcttpccecctwacaeteag

-

94°C 2min; 94'C

OW58

-

OW58
aaagatctttaeccaacaactttatth

- 30sec;

- 30sec; 72°C - lmin

55'C

(C and N terminally tagged)

94°C 2min; 94'C

- 30sec;

53°C - 45sec; 68'C

- lmin

aagaattcttecceccteeacaeteag

(N terminally tagged)

94°C - 2min; 94°C - 30sec;

OW58

aaagatctggccaacaactttatttattaccg

aagaattcaccatetgcce.ccte~acaeteae;

OW27

-

6I0C -45sec; 6S°C lmin

(C terminally tagged)

!

PCR Conditions

atgaattcaccaeteacacaccttta

aaagatctQcgtcatcteatattctg

47'C

'I

- 30sec; 72°C - lmin

1

1

Table 1: List of OW58 and OW27 primers and their respective PCR conditions. V i s specific sequence
is underlined and the sequence of the restriction enzyme sequence is in red.

Transformation

Frozen E. coli DH5a competent cells were thawed on ice, gently mixed and 50 p1
aliquots were transferred into labeled tubes. The ligation reactions, five pl each, were
then added to the dispensed cells and gently mixed. The ligationlcell mixture was
incubated on ice for 30 minutes. The cells were then heat shocked at 42OC for 60 seconds
and then placed on ice for two minutes. After resting on ice, 450 p1 of LB was added to
the transfected cells. The cells were then transferred to a 37OC water bath for one hour.
The appropriate volume (100-200 p1) of transformed cells were spread on LB agar plates
containing either ampicillin or kanamycin (100 pg/ p1) and incubated at 37OC overnight.
Transfection

Vero, African green monkey kidney, cells were plated at a concentration of
2 . 0 ~ 1 0cells/well
~
and incubated for 24 hours at 37"C15% C02 in two ml of Dulbecco's

Modified Eagle Medium (DMEM) (Mediatech Inc) supplemented with 1% penicillinstreptomycin (Mediatech Inc) and 10% fetal bovine serum (PAA laboratories). Transient
transfection was carried out using GeneJuice (Novagen) according to manufacturer's
instructions. A mixture of Genejuice (three p1) and serum free DMEM (100 p1) was
created for each variable. The tubes were then incubated at room temperature for five
minutes. Afterwards, one pg of extracted clone DNA was added to the appropriately
labeled DMEMiGenejuice mixture and incubated 15-20 minutes at room temperature.
After incubation, DMEM/Genejuice/clone DNA mixtures were added to Vero cells and
cells were grown for 48 hours at 37OC/5% COz.
Protein Extraction

Forty eight hours post-transfection, cells were rinsed with phosphate buffer saline
(PBS). Lysis buffer [SO mM Tris-HC1 (pH 7.5), 120 mM NaCl,5 mM EDTA, 0.5% NP40,50 mM NaF, 0.2 mM Na3V04, 1 mM DTT, 1 mM PMSF or 1 Complete protease
cocktail tablet (Roche) with 1 mM DTT] was then added to the adherent cells in the well.
After addition of the lysis buffer, cells were scraped with a plastic scraper and placed into
a microcentrifuge tube on ice. The scraped cells were then incubated on ice for ten
minutes with periodic vortexing. Cells were then centrifuged (12,000 rpm) at 4OC for ten
minutes. The supernatant was transferred to a new tube and the pellet was discarded.
The extracted protein samples were stored at -80°C.
Extracted protein concentrations were calculated using a spectrophotometer. A
standard curve was created using bovine gamma globulin (Bio-Rad) at increasing
amounts (one, three, five, and ten micrograms) in one ml of protein determination reagent

Bradford dye (USB). The optical density for protein samples were analyzed at 595 nm.
An aliquot of the extracted protein samples were added to one ml of Bradford dye and
optical density was recorded at 595 nm. The gamma globulin standard curve was then
used to calculate the protein concentrations of the extracted protein samples.

SDS PAGE and Western Blot
A 10% SDS PAGE gel was used to separate the protein extracts. The SDS PAGE
resolving gel consisted of the following: 375 mM Tris (pH 8 . Q 10% acrylamide, 0.1%
SDS, 0.1% ammonium persulfate, 0.04% TEMED. The stacking gel was made up of: 5%
acrylamide, 125 mM Tris (pH 6 4 , 0.1% SDS, 0.1 % ammonium persulfate, 0.1%
TEMED. Extracted proteins were prepared with SDS loading buffer (125 mM Tris pH
6.8,4% SDS, 20% Glycerol, 10% P-Mercaptoethanol, 200 mM DTT and 0.002%
bromophenol blue) and boiled at 100°C for five minutes. Samples then were loaded and
run on SDS PAGE gel at 100-150 volts. The separated proteins were then transferred
onto a nylon Immobilon P membrane (Millipore) using a cathode core filled with transfer
buffer (20% methanol, 0.1% SDS, 1X transfer buffer [lo0 mM Glycine, 12.5 mM TrisHCI pH 8.31 and deionized water) overnight at 0.08 amps.
Afier the overnight transfer, the membrane was blocked with non-animal proteinblocker (NAP) (GBiosciences) diluted 1:2 in TBST (25 mM Tris-HC1 (pH KO), 125 mM
NaC1,0.1% Tween-20). The membrane was blocked, one to four hours, at room
temperature with rocking. Primary antibodies were diluted 1:1000 in 1:4 NAPITBST (10
ml total volume) and incubated, one to four hours, at room temperature with rocking. The
primary antibody used for phCMV2-ORF27 was HA.11 monoclonal antibody raised in

mouse (Covance) and the primary antibody for p3XFLAG-ORF58 was ANTI-FLAG M2

monoclonal antibody (Sigma-Aldrich) developed in either mouse or rabbit. Afterwards,
the membrane was then washed four times with TBST, ten minutes each wash.
After the TBST washes the secondary antibody, anti-mouse or anti-rabbit IgG
horseradish peroxidase (HRP)-linked antibody (Cell-Signaling), was diluted 1:1000 in
TBST (ten ml total volume) and added to the membrane. The membrane was incubated
with the secondary antibody for one to four hours at room temperature with rocking. The
membrane was then washed with TBST as described previously. The ECL Plus Western
Blotting Detection Reagent (GE Healthcare) was used, according to manufacturer's
instructions, to detect any immobilized HRP-linked antibodies on the membrane. Finally,
the membrane was scanned on the STORM Scanner 860 (Molecular Dynamics)
phosphoimager to visualize the protein bands. The background and contrast levels of the
scanned images were adjusted with ImageQuant 5.2.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Reverse transcription PCR was used to observe if OW58 DNA was being
transcribed into RNA in cells after transfection. Vero cells were transfected with OW58
constructs as detailed above. Forty eight hours post-transfection, total RNA was
extracted using RNA spin mini RNA isolation kit (GE Healthcare), according to
manufacturer's instructions. RNA concentrations were quantified using a
spectrophometer at 260 nrn. The extracted RNA samples were diluted 1:I00 in sterile
water and then transferred to quartz cuvettes. The reading observed at 260 nm multiplied

by the dilution factor and 40 pg/ ml (equivalent to one A260 unit) will give the
approximate concentration of RNA.
RNA samples, two pg total, were then treated with RQ1 RNase-Free DNase
(Promega) for 30 minutes at 37°C. A one p1 aliquot of DNase stop solution (Promega)
was added to the RNA samples to terminate the DNase reaction; which was followed by
65OC incubation for ten minutes. The RNA samples (1 pg, 9.1 p1 each) were incubated
for ten minutes at 70°C, followed by ten minutes at 4'C. RT master mix was prepared
with the RT-PCR kit (Promega) as follows (20 p1 total volume): 5 mM MgCl2, 1X RT
buffer, 1 mM dNTP mix, 0.5 p1 recombinant RNasin ribonuclease inhibitor, 0.6 pl AMV
reverse transcriptase and 0.025 pg/ pl Oligo(dT)l5 primer. A "no RT" master mix was
prepared without RT, RNasin and O l i g ~ ( d Tprimer.
)~~
Samples prepared without RT,
RNAsin, and Oligo(dT)ls would identify any possible DNA contamination in the RNA
samples. The RT and "no RT" master mixes were then added to the RNA samples. The
reaction was then carried out at 4 2 T - 30 minutes, 95OC - five minutes, and 10°C over
night.
PCR was then carried out with new OW58 primers that were used to amplify a
small portion of the sequence. The primers created were: 3'cagcatgctcacgaggaata, 5'
tcctgattggcctggataag. GAPDH primers were used as a positive control for RT-PCR. The
PCR consisted of the following: 10 p1 RT reaction, 50 pmol primer mix, 25 p1 Master
mix (Promega) and nuclease-free water. The PCR conditions were as follows: 94'C-30
seconds, 55T-30 seconds, 72°C-30 seconds for 30 cycles. RT-PCR reactions were then

run and visualized on a 1% agarose gel.

Immunofluorescence
Coverslips and slides were acid washed in 1 M HC1 solution heated at 50'-60°C
for four hours, cooled to room temperature and then rinsed in 100% ethanol. Treated
coverslips were placed on the bottom of wells prior to adding Vero cells. To each well,
2 . 0 ~ 1 0cells
~ were then added and cells were grown for 24 hours at 37'C/5% C02. The
transfections were performed as outlined above. Cells were rinsed in PBS, 48 hours post
transfection, and fixed to the coverslips with 3.7% paraformaldehyde solution at
37"C/5% C02 for 30 minutes.
Fixed cells were then covered with blocking buffer (1% bovine serum albumin in
PBS) for 30 minutes at 37'C/5% C02. Blocking buffer was then removed and the
primary HA-Tag rabbit monoclonal antibody (Cell Signaling) was added to the
coverslips. Coverslips were incubated one hour at room temperature and subsequently
washed three times in PBS. Transfected cells were then incubated with secondary
antibody conjugated to a fluorochrome Alexa floura 488 rabbit IgG (Invitrogen) for
ORF27. Cells were incubated one hour at room temperature then washed three times
with PBS. DAPI stain solution was then added to cells for five minutes at room
temperature. Each coverslip was then inverted onto a slide containing ten p1 of Cytoseal
mounting media (Richard-Allan Scientific). Any excess media was removed and the
edges of each coverslip were sealed with transparent nail polish. Proteins of interest were
visualized using the Olympus Fluoview FV1000 confocal microscope. The argon laser
was used to excite Alexa 488 fluorophore and the diode blue 405 was used to excite the
DAPI stain.

Results

ORF27 and ORF58 sequence comparisons
In order to determine ORF27 and ORF58 sequence similarities to EBV and
MHV-68, all sequences were aligned using ClustalW2, a sequence alignment program for
DNA or proteins (Chenna et al., 2003). EBV BDLF2 and MHV-68 ORF27 were
predicted to encode type I1 transmembrane glycoproteins with N-linked glycosylation
sites (Gore et al., 2009; May et al., 2005b). Figure 1A illustrates the sequence alignment
between KSHV OW27 and its homologues. Identification of the N-linked glycosylation
sites were accomplished using NetNGlyc 1.0 Server, a prediction program (Blom et al.,
2004). The glycosylation program showed multiple N-linked glycosylation sites in the
extracellular regions of all ORF27 homologues. There was also a marked difference
observed in the lengths of OW27 homologues cytoplasmic tails. The KSHV ORF27
cytoplasmic tail was 82 amino acids shorter than EBV BDLF2 and 32 amino acids longer
than MHV-68 ORF27.
The ORF58 alignment was enhanced using information provided by May et al.
(2005). EBV BMRF2, MHV-68 ORF58 and KSHV OW58 are predicted to contain 11
transmembrane (TM) regions (May et al., 2005a). We see in Figure lB, the TM regions
had high numbers of identical, conserved and semi-conserved amino acids. As per May
et al. (2005), KSHV ORF58 protein had 11 TM domains, equivalent to both MHV-68

ORF58 and BMRF2. May et al. (2005) used EC4 in EBV BMRF2, the largest
hydrophilic loop, as a point of reference to determine the other hydrophilic domains. The

RGD motif, within the EC4 region, is important in virion attachment and cell to cell viral
spread (Xiao et al., 2007). The RGD motif was not observed in either MVH-68 (ORF58)
or KSHV (ORFS8) (Figure IB).
Cloning of ORF27 and ORF58
To study ORF27 and ORFS8, the genes were cloned into mammalian expression
plasmids. The genes were amplified using PCR and cloned into phCMV-2 and
p3XFLAG-14, respectively. PCR was carried out using gene specific primers and
BCBL-1 genomic DNA. Figures 2A and 2B confirm the specificity of the primers to
amplify the genes of interest at the expected sizes of 874 bp for OW27 and 1094 bp for
ORFS8. The bands observed were consistent with the nucleotide sequence lengths of
OW27 and ORFS8 as described by Russo et al. (1996). Afier PCR and gel purification,
ORF27,ORF58, and the plasmids were digested sequentially with EcoR I and Bgl 11.
Following double digestion, the genes and plasmids were purified and ligation was
carried out. The ligated OW27 and ORF58 plasmids were then transformed into E. coli
strain DHSa. DNA was isolated from colonies that were picked and grown overnight.
The isolated DNA was double digested with EcoR I and Bgl 11. In Figures 2C and 2D we
observed positive clones for both phCMV-2-OW27 (five total) and p3XFLAG-14ORFS8 (ten total).
Selected clones were sent to Genewiz for sequencing. ORF27-C1 and C10
sequences were compared to the KSHV nucleotide sequence. KSHV ORF27-C1 had
98% identity to the published KSHV ORF27 sequence (accession number AACS7108.1)
and KSHV ORF27-C10 had 96% identity (data not shown). Due to the higher percent

Figure 1. Sequence analysis of KSHV O W 2 7 and ORF58. Sequence analysis of KSHV OW27 and
OW58 was performed using ClustalWZ. A. Alignment results of MHV-68 (OW27), KSHV (OW27), and
EBV pDLF2). Identification of N-linked glycan attachment sites, highlighted in grey, were done using
NetNGlyc 1.0 Server program. B. Alignment results of MHV-68 (ORF58), EBV (BMRFZ), and KSHV
(ORF58). Transmembrane regions were underlined for KSHV OW58 and its homologues. Extracellular
domain 4 (EC4) is highlighted in yellow and the RGD motif, within EC4, is highlighted in green.

Figure 2: Cloning of phCMV2-OW27 and p3XFLAG14-ORF58. A. PCR amplification of OW27
using gene specific primers and BCBL-1 genomic DNA. B. PCR amplification product of ORF58. C.
pbCMV-2-OW27 clones double digested with EcoR I and Bgl 11. lkb DNA ladder (lane l), phCMV-2
control (lane 2), double digested clones 1-10 (lanes 3-12). D. p3XFLAG-14-OW58 clones double digested
with EcoR I and Bgl 11. lkb DNA ladder (lane l), p3XFLAG-14 control (lane 2), double digested clones 1I0 (lanes 3-12), OW58 insert control (lane 13).

identity, ORF27-C1 was used for subsequent analyses. The sequence results for KSHV
ORF58-C3 and C8 revealed 96% identity to the published KSHV OW58 sequence
(accession number AAC57143.1) (data not shown).

Protein expression of K S W OW27 and ORF58 clones
To determine if protein expression would be observed, a western blot analysis
was performed on OW27 and ORF58 clones expressed in mammalian cells. The ORF27
insert was N-terminally tagged with an in-frame HA fusion protein. ORF58 was tagged
with an in-frame 3XFLAG fusion protein. A total of three ORF58 constructs were
created; they included an N-terminal3XFLag tag, a 3XFLAG N- and Myc C-terminal tag
and finally a 3XFLAG C-terminal tag insert. The phCMV2-ORF27 and p3XFLAGOW58 constructs were transfected into Vero cells, total protein was extracted, separated
on a 10% SDS-PAGE gel, and western blot analysis was carried out. The expected size
of the ORF27 fusion protein was 34.5kDa. In Figure 3A, a band of approximately 34.5
kDa was observed in lanes 4 and 5 indicating that ORF27 was successfully expressed
from the phCMV2 plasmid. Some non-specific bands were also observed but the ORF27
bands were intense in comparison. A 4lkDa band, which would correspond to the
OW58 fusion protein, was not observed (Figure 3B) (C-terminal tag). An intense band
for the positive control FLAG-V-cyclin-C7 was observed in lane 4 verifying the
transfection and western blot worked properly. Similar results were observed for all
other ORF58 constructs (data not shown). The OW58 fusion protein was never observed
in any western blot analyses. Another mammalian cell line, 293T, was also used;
however, expression of the ORF58 fusion protein was not observed (data not shown)

phCMV-2-OW27 clones

p3XFLAG-14-OW58 clones

Figure 3. Protein expression of phCMV-2-ORFZ7 and p3XFLAG-14-ORF58. phCMV2-OW27 and
p3XFLAG-OW58 clones were transfected into Vero cells, total protein was extracted, run on 10% SDSPAGE gel and then analyzed via western blot. A. OW27 protein expression. Full range rainbow GE
Healthcare molecular weight marker (lane I), negative control mock transfected Vero cells (lane Z),
pbCMV-2-ORF27-C1 (lane 3), phCMV-2-ORF27-C10 (lane 4). The expected size of the HA-OW27
fusion protein was 34.5 kDa. B. OW58 protein expression. Full range rainbow GE Healthcare molecular
weight marker (lane I), p3XFlag-14-ORF58-C3 C-tern tag (lane 2), p3XFlag-14-OW58-Cg C-term tag
(lane 3), positive control vCyclin clone 7 (lane 4), negative control mock transfected Vero cells (lane 5).
The expected size of the 3XFlag-ORF58 fusion protein was 41 kDa.

Detection of ORF58 mRNA by RT-PCR
To examine possible reasons why the OW58 hsion protein was not expressed,
total RNA of p3X-FLAG-ORF58 transfected cells were analyzed for the presence of
ORF58 mRNA. Vero cells were transfected with ORF58 clones including N-terminal
tag, C-and N-terminal tag, and C-terminal tag clones. Total RNA was isolated from the
cells. Reverse transcriptase converted mRNA to cDNA. PCR was then carried out with
gene specific primers to amplify the targeted DNA. As a control, the ORF58 samples
were also run without RT (Figure 4A, lanes 8-13) which would identify DNA
contamination in the isolated RNA samples. The OW58 samples where mRNA was
observed were the C-terminal tag (lanes 2-3) and the C- and N-terminal tag (lane 6)
clones. In Figure 4B, GAPDH positive control bands were observed confirming that
mRNA was properly reverse transcribed and amplified in all samples. The presence of
OW58 mRNA would indicate the DNA was being transcribed in the cell.

Figure 4. Detection of OW58 mRNA with RT-PCR. P3XFLAG-OW58 constructs were transfected
into Vero cells, total RNA was collected and reverse transcription-PCR was performed. OW58 RT-PCR
product is 206 bp in length A. OW58 RTPCR product m on agarose gel. lOObp DNA ladder (lane I),
p3XFLAG-14126-OW58 clones with RT (lanes 2-6), p3XFlag-14 vector with RT (lane 7), and control
reactions without RT (lane 8-13). B. GAPDH primers were used as a positive control for all reactions with
RT. lOObp DNA ladder (lane l), p3XFLAG-14126-OW58 clones (lanes 2-6), p3XFlag-14 vector (lane 7).

ORF27 protein visualization by means of immunofluorescence
In order to visualize the localization of the KSHV ORF27 fusion protein an
immunofluorescence assay was performed. After the expression of the OW27 fusion
protein was verified by western blot analysis, phCMV-2-ORF27-C1 clone was then
transfected into Vero cells to determine sub-cellular localization of ORF27. Vero cells
were grown onto coverslips and transfected with phCMV2-ORF27-C1 clone. Forty eight
hours post-transfection cells were fixed, stained with specific antibodies, counter stained,
and mounted onto slides. The cells were observed using a confocal microscope. ORF27
protein was observed throughout the cytoplasm of the cell (Figure 5A) and was not
localized to the plasma membrane. This is similar to what Sander et al. (2008) observed
for KSHV ORF27 localization. The phCMV2 control transfection showed no
background immunofluorescence (Figure 5B).

Figure 5. Expression of ORF27 in the Cytoplasm of Vero cells. Vero cells were grown onto coverslips
and transfected with phCMV2-ORF27-C1. Cells were fuced in 3.7% paraformaldehyde, blocked in 1%
BSAIPBS. Cells were stained with primary and secondary antibodies. The nuclei were counter stained
with DAPI (blue). Coverslips were mounted and images were taken using a confocal microscope. A. HAORF27-C1 fusion protein (green), B. phCMV2 vector only control.

Discussion

KSHV was discovered by Chang et al. in 1994 and has since been found to be the
cause of Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's
disease (Ablashi et al., 2002). KSHV is an enveloped gamma herpesvirus with many
different glycoproteins (Russo et al., 1996). Enveloped viruses have a lipid layer that
surrounds the nucleoprotein core; therefore, entry into the host cell requires either fusion
between the cell membrane and the envelope or endocytosis of the virus into the cell
(Greene et al., 2009; Knipe et al., 2001). Glycoproteins play a critical role in attachment,
entry, and possibly virion egress (Chandran, 2010; Subramanian et al., 2010).
Consequently, it is vital that all known and any possible KSHV glycoproteins are
examined to better understand the processes of entry and egress. KSHV OW27 and
ORF58 are possible glycoproteins but their functions are unknown (Chandran et al.,
1998; Russo et al., 1996).

In this study we examined the localization of KSHV ORF27 and 58. It has been
shown that the OW27 and OW58 homologues in both EBV and MHV-68 form a stable
protein complex that co-localize at the plasma cell membrane when they were coexpressed (Loesing et al., 2009; May et al., 2005a). Both KSHV ORF27 and OW58
were positively cloned into vectors for mammalian expression (Figures 2C and 2D). We
attempted to observe the co-localization of KSHV ORF27 and ORF58 fusion proteins;
however, we were unable to properly express the OW58 fusion protein. The OW27
fusion protein was successfully expressed and observed within the cytoplasm of

mammalian cells (Figure 3A and Figure 5A). Due to the lack of the ORF58 protein
expression we were not able to examine the co-localization of KSHV ORF27 and OW58
proteins.
When we examined the protein sequence alignment of OW27 we noticed the
differences in the length of the cytoplasmic tail for the ORF27 homologues (Figure 1A).
The KSHV OW27 cytoplasmic tail was 82 amino acids shorter than EBV BDLF2 and 32
amino acids longer than MHV-68 ORF27. No documentation has been published on the
significance of the cytoplasmic tail length for KSHV ORF27 or EBV BDLF2. However,
Gill et al. (2008) found that a truncated cytoplasmic tail of MHV-68 OW27 stopped the
creation of fronds. Fronds are finger like protrusions of the cell membrane that are
created by actin rearrangement within the cell (Gill et al., 2008). The many fronds
increase the surface area and extend the cell membrane which may aid in viral infection
to uninfected cells (Gill et al., 2008). MHV-68 OW27 and O m 5 8 induce actin
rearrangement causing the creation of these fronds (Gill et al., 2008). Therefore, the
MHV-68 OW27 cytoplasmic tail was needed for actin rearrangement (Gill et al., 2008).
The cytoplasmic tail is thought to interact with RhoA-dependent signaling pathways
leading to actin polymerization (Gill et al., 2008). Gill et al. (2008) also observed EBV
BDLF2 and BMRF2 created similar fronds, but did not examine BDLF2 cytoplasmic tail
truncation. Due to the similarity in the sequence analysis and the observations of Gill et
al. (2008) for both MHV-68 OW27 and EBV BDLF2, I would speculate the KSHV

OW27 cytoplasmic tail, which is shorter than BDLF2 and longer than MHV-68 ORF27,
may also function in actin rearrangement.

In addition to attachment/entry, the MHV-68 ORF27 protein may also protect the
EC4 region on the OW58 protein from host antibodies (May et al., 2005a). The
extracellular domain of the MHV-68 ORF27 protein contains many N-linked
glycosylation sites which, when heavily glycosylated, may assist in the protection of the
EC4 region. The EC4 domain is similar to the RGD containing domain in EBV BMRF2
in that it can aid in binding to cells via cell surface integrins (May et al., 2005a; Xiao et
al., 2009). The N-linked glycosylation sites were observed in the KSHV ORF27 and

BDLF2 protein sequence alignment (Figure 1A) which suggests that the protein would
also be glycosylated and possibly function to protect the EC4 domain in the OW58
homologues. This protection would allow for the virus to evade the host immune system.
In the ORF58 protein sequence alignment we observed that all ORF58
homologues contained the 11 transmembrane domains. The RGD motif observed in the
EC4 region of BMRF2, which is needed to bind to the basal membrane of polarized
epithelial cells (Xiao et al., 2007). The equivalent EC4 loop in MHV-68 OW58 has
been shown to bind to uninfected cell surfaces (May et al., 2005a), but polarized cells
were not specifically mentioned in the article. KSHV ORF58 does not contain an RGD
motif in the EC4 region but there was high identity and conserved amino acids observed
in the region. Due to the similarities observed in the sequences of the OW58
homologues we would speculate that KSHV ORF58 would also aid in binding to the
surface of host cells enabling cell to cell spread similar to what has been observed in both
MHV-68 and EBV (May et al., 2005a; Xiao et al., 2007).

When KSHV ORFS8 was not observed in western blot analysis we thought there
could be a mutation occurring the in the clone DNA. The ORF58 constructs were
transformed into E. coli DH5a cells. During replication a novel mutation may have been
incorporated into the clone DNA, which could disrupt its protein expression. Mutation
frequencies differ among E. coli strains and changing the E. coli strain used in
transformation may lead to lower mutation frequency. Therefore, we transformed the
p3XFLAG-14-ORF58 constructs into a different strain of E. coli called JM109 in an
attempt to create clone DNA with fewer possible mutations. Clones created in the JM109

E. coli strain were transfected into mammalian cells, western blot analysis was performed
and no protein bands were observed that would correspond to the ORF58 fusion protein
(data not shown). We then looked into the placement of the tags. A C- or N-terminal
tag may interfere with protein function and our construct was both C- and N-terminally
tagged. We created new OW58 constructs, an N-terminal tag and a C-terminal tag. Yet
again, we did not observe protein on western blot analysis. Gore et al.(2008) observed
problems with ORF58 protein expression on western blot which they attributed to the
protein being highly hydrophilic. The researchers used a urea based SDS-PAGE gel and
were able to observe the ORF58 protein (Gore et al., 2009). We attempted to run the
ORF58 clone protein extracts on a urea containing SDS-PAGE gel, but still did not
observe expression of the fusion protein.
We then investigated ORF58 mRNA production within the transfected
mammalian cells. If no mRNA was observed this would lead us to believe there was
something wrong with transcription of the insert. We used RT-PCR to determine if

mRNA was produced. We found that mRNA was being transcribed for the C-terminal
tag and the double tag constructs (Figure 4A). We speculate the problem of ORF58's
protein expression could be due to degradation of a misfolded protein, or protein
translation was halted for some reason. Further experiments need to be conducted to pin
point the source of the problem.
Sander et al. (2007) determined the localization patterns of KSHV ORF27 and
ORF58 following transfection of HeLa cells. ORF27 was observed throughout the
cytoplasm heterogeneously (Sander et al., 2007) similar to the localization we had
observed for ORF27 (Figures 5A). MHV-68 OW27 and BDLF2 were found to be
expressed within the ER when transfected without the ORF58 homologues (Gore et al.,
2009; May et al., 2005b). We observed similar a localization pattern in KSHV OW27
which supports our theory that the protein would be found throughout the cytoplasm
when transfected without KSHV ORF58. Sander et al. (2007) found OW58 was
subcellularly localized in the TGN. We theorized that OW58 may be expressed if
OW27 was also present in the cell. In attempt to visualize the ORF58 fusion protein we
co-transfected the ORF27 and 58 clones into mammalian cells, but O W 5 8 protein was
still not observed (data not shown).
In conclusion, KSHV ORF27 was successfully cloned into the phCMV-2 vector.
The gene was properly expressed in mammalian cells and observed via western blot
analysis and by means of immunofluorescence. KSHV ORF27, when expressed alone,
was observed in the cytoplasm of the cell and not on the cell surface as was hypothesized.
The localization of KSHV ORF27 within the cell and not at the cell surface may mean

the protein was not fully processed; therefore, it could not he translocated to the cell
surface. KSHV ORF58 was successfully cloned three times into the p3XFLAG vector,
and was tagged at the C- and N- terminus, the C-terminus, and the N terminus. The RTPCR experiment demonstrated that KSHV ORF58 mRNA was transcribed for some
clones, but the other clones may have had mutations which did not allow for mRNA
production. KSHV ORF58 protein was never observed on western blot analysis or
immunofluorescence (data not shown). Future experiments would include looking at
possible pathways of protein degradation for ORF58. If protein degradation can be
halted then co-localization experiments can be carried out with co-transfection of KSHV
ORF27. Finally, observing possible specific protein interactions between KSHV OW27
and ORF58 would confirm they form a protein complex similar to that observed in EBV
and MHV-68 (Loesing et al., 2009; May et al., 2005a).
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